Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

SHERMAN, Texas, Jan. 8, 2024 /PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise acquired the common stock of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) (the "Settlement Class"), including all persons or entities who purchased or otherwise acquired Reata common stock pursuant and/or traceable to Reata's 2019 Offering and/or 2020 Offering (the "Offerings Subclass"). PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company's previously announced acquisition (the “Merger”) by Biogen Inc., a Delaware corporation (“Biogen”). Appr.

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

Cabaletta Bio

FingerMotion

Limbach Holdings

MoonLake Immunotherapeutics

Opera Ltd - ADR

Super Micro Computer

Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum investing hinges on the principle that assets that have performed well recently will continue to do so in the near future.

The 7 Most Promising Momentum Stocks to Own Now

Eli Lilly

Madrigal Pharmaceuticals

It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe diseases. These companies not only do a good job of researching and developing cures, but they also have an incredible financial performance.

The 3 Most Promising Pharma Stocks to Own Now

Biogen

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Reata Pharmaceuticals, Inc. (NasdaqGM: RETA) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Reata will receive $172.50 in cash for each share of Reata that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

Disc Medicine Inc

NVIDIA

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

These Are The 5 Best Stocks Of The Year; Some You May Not Recognize

REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.

Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs

Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma company for $7.3 billion. Why is Biogen making this acquisition?

Reata Pharmaceuticals stock opened 50% up on Friday: what happened?

MILWAUKEE , July 28, 2023 /PRNewswire/ -- Ademi LLP is investigating Reata (Nasdaq: RETA) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Biogen.  Click here to learn how to join the action https://www.ademilaw.com/case/reata-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Reata Pharmaceuticals, Inc. has obtained a Fair Price in its Private Placement and its transaction with Biogen

Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That deal has Biogen offering to buy shares of RETA stock for $172.50 per share in cash.

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

Biogen Inc (NASDAQ:BIIB) said it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion in cash as it bulks up its neuromuscular and rare disease portfolio. Shares of Reata shot up 52% to $165 on news of the $172.50 per share offer.

Biogen to acquire Reata Pharmaceuticals for $7.3B

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

Reata stock surged more than 50% on the news.

Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) to Biogen Inc. for $172.50 per share in cash is fair to Reata shareholders. Halper Sadeh encourages Reata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Reata and its.

RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders

The deal would bolster the biotech company's portfolio of treatments for neuromuscular and rare diseases.

Biogen to Buy Reata in $7.3 Billion Deal

Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.

Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.

Biogen said it would buy biotech firm Reata Pharmaceuticals for roughly $6.5 billion to expand its presence in the rare disease drugs market.

Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio

Biogen Inc. BIIB, -0.93% said Friday it has agreed to acquire Reata Pharmaceuticals Inc. RETA, +2.32% for $7.3 billion in cash. Reata “has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases,” Biogen said in a statement.

Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash

CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

Biogen to Acquire Reata Pharmaceuticals

Reata CEO Warren Huff says Friedreich's ataxia is "the worst disease." Now, RETA stock investors are watching the long-awaited drug launch.

Reata Surges 16% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug

Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.

Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7%

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

Reata Pharmaceuticals won the FDA's blessing to launch its Friedreich's ataxia drug, and RETA stock surged Wednesday.

News for Reata Pharmaceuticals Stock (RETA)